Abacus FCF Advisors LLC Makes New $13.11 Million Investment in Bristol Myers Squibb Company $BMY

Key Points

• Abacus FCF Advisors purchased 227,584 Bristol Myers Squibb shares worth approximately $13.11 million, making BMY its 11th-largest holding and representing 2.4% of its portfolio. Institutional investors own 76.41% of the stock.
• Bristol Myers Squibb exceeded quarterly expectations, reporting $2.04 in adjusted EPS versus the $1.60 consensus and revenue of $12.97 billion, up 5.7% year over year. Analysts expect about $6.95 in full-year EPS.
• BMY offers an annualized $2.52 dividend, yielding roughly 3.7%. The stock had a “Moderate Buy” consensus rating, with a $66.06 average price target and recent bullish targets as high as $75.

Abacus FCF Advisors LLC acquired a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 227,584 shares of the biopharmaceutical company's stock, valued at approximately $13,113,000. Bristol Myers Squibb comprises approximately 2.4% of Abacus FCF Advisors LLC's holdings, making the stock its 11th biggest position.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Brighton Jones LLC boosted its holdings in shares of Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock worth $1,116,000 after buying an additional 4,935 shares during the last quarter. Sivia Capital Partners LLC raised its position in Bristol Myers Squibb by 59.4% in the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company's stock worth $346,000 after acquiring an additional 2,786 shares during the period. United Bank boosted its stake in Bristol Myers Squibb by 15.0% in the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company's stock valued at $1,164,000 after acquiring an additional 3,277 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at approximately $221,000. Finally, Nebula Research & Development LLC bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $405,000. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Trading Up 2.3%

NYSE:BMY opened at $67.59 on Thursday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $68.64. The stock's fifty day moving average price is $60.18 and its two-hundred day moving average price is $59.24. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The company has a market cap of $138.06 billion, a P/E ratio of 14.89, a P/E/G ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to analysts' expectations of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm's quarterly revenue was up 5.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, analysts expect that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.7%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb's dividend payout ratio is presently 55.51%.

Wall Street Analyst Weigh In

BMY has been the subject of several research reports. JPMorgan Chase & Co. increased their price objective on Bristol Myers Squibb from $67.00 to $73.00 and gave the company an "overweight" rating in a report on Friday, July 31st. Roth Capital began coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a "buy" rating and a $75.00 price target for the company. Weiss Ratings raised Bristol Myers Squibb from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday. Wells Fargo & Company set a $65.00 price objective on Bristol Myers Squibb and gave the company an "equal weight" rating in a research note on Friday, July 31st. Finally, Raymond James Financial started coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They set a "strong-buy" rating on the stock. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $66.06.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source